kl05077.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of
report (Date of earliest event reported) May 22, 2007
Nephros,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Commission
File Number: 001-32288
|
Delaware
|
|
13-3971809
|
|
(State
or other Jurisdiction of
Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
3960
Broadway, New York, New York 10032
(Address
of Principal Executive Offices)
(Zip
Code)
(212)
781-5113
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
r
Written
communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
r
Soliciting
material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
r
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
r
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b)
On May 22, 2007, Dr. Bernard Salick
submitted to Nephros, Inc. (the “Company”) his resignation from the Company’s
Board of Directors (the “Board”) effective immediately to pursue other business
interests. Dr. Salick had no disagreements with the Company on any
matters related to the Company’s operations, policies or
practices. The Board thanks Dr. Salick for his dedicated service and
valued contributions to the Company.
Item
8.01 Other Events.
On
May
23, 2007, the Company issued a press release announcing the resignation of
Dr.
Salick from the Company’s Board. The full text of this press release
is attached hereto as Exhibit 99.1. The information in this Item 8.01
shall not be deemed to be “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the liability of that
Section.
Item
9.01. Financial Statements and Exhibits.
99.1 Press
Release issued by Nephros, Inc. dated May 23, 2007.
SIGNATURES
Pursuant
to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report
to
be signed on its behalf by the undersigned hereunto duly
authorized.
Date: May
23, 2007
NEPHROS,
INC.
By:
/s/ Mark W.
Lerner
Mark W. Lerner
Chief Financial Officer
(Principal Financial and Accounting Officer)